Related Experiment Videos
Antirifampicin antibodies in acute rifampicin-associated renal failure
Abstract:
5 patients with acute renal failure (3 with thrombopenia and hemolysis) induced by the reintroduction of rifampicin are described. No correlation was found between the severity of clinical manifestations and the total dose taken by the patients. In all but 1 patient, antirifampicin antibodies were detected. Antibodies suggested to be of the IgM class were detected in all 3 patients with hematological disorders. The pattern of non-specific acute tubular necrosis found in the 2 biopsied patients, indistinguishable from that of ischemic origin, raised the possibility of a vascular-mediated damage. In 3 patients, the possibility of a triggering immunoallergic mechanism is discussed.
Insights
Rifampicin reintroduction caused acute renal failure in 5 patients, often linked to antirifampicin antibodies. Immunoallergic mechanisms may trigger these severe reactions, even without dose correlation.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Rifampicin is a crucial antibiotic for tuberculosis treatment.
- Acute renal failure (ARF) is a potential adverse effect of drug therapy.
- Immunoallergic reactions can manifest with diverse clinical presentations.
Observation:
- Five patients developed acute renal failure following rifampicin reintroduction.
- Three of these patients also presented with thrombocytopenia and hemolysis.
- Antirifampicin antibodies were detected in four patients; IgM antibodies were found in those with hematological issues.
Findings:
- No correlation was observed between rifampicin dosage and ARF severity.
- Renal biopsy in two patients revealed non-specific acute tubular necrosis, suggesting vascular-mediated damage.
- An immunoallergic mechanism is proposed as the cause of ARF in some patients.
Implications:
- Clinicians should consider immunoallergic mechanisms in rifampicin-induced ARF, especially with hematological involvement.
- Monitoring for ARF and hematological parameters is crucial during rifampicin therapy.
- Further research into the immunopathogenesis of rifampicin adverse effects is warranted.